Last update 19 Jun 2024
SHR-A1921
Last update 19 Jun 2024
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms SHR A1921, SHR-1921, SHR-A1921 + [1] |
Target |
Mechanism Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Breakthrough Therapy (CN) |
Structure
Boost your research with our XDC technology data.
login
or
Related
17
Clinical Trials associated with SHR-A1921A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
An Open, Multicenter Phase I/II Trial of SHR-A1921 in Combination With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
A Randomized, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
100 Clinical Results associated with SHR-A1921
Login to view more data
100 Translational Medicine associated with SHR-A1921
Login to view more data
100 Patents (Medical) associated with SHR-A1921
Login to view more data
100 Deals associated with SHR-A1921
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Platinum-Resistant Epithelial Ovarian Carcinoma | Phase 3 | CN | 09 May 2024 | |
| Platinum-Resistant Epithelial Ovarian Carcinoma | Phase 3 | CN | 09 May 2024 | |
| Ovarian Epithelial Carcinoma | Phase 3 | - | 15 Feb 2024 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 04 Jun 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 30 Dec 2022 | |
| Advanced cancer | Phase 1 | CN | 20 Jan 2022 | |
| Advanced cancer | Phase 1 | CN | 20 Jan 2022 | |
| KRAS G12D mutation Solid Tumors | IND Approval | CN | 02 Apr 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05154604 (AACR2023) Manual  | Phase 1 | HR-positive/HER2-low Solid Tumors Second line | 38 | hwcbdnugeu(aehbgzggjv) = aihvoybgzu axnxxlygfl (wfgjsvzpep ) View more | Positive | 14 Apr 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free